Investigating the effect of curcumin capsules on cisplatin-induced kidney damage

Evaluation the Effect of Curcumin Capsules on Prevention of Nephropathy Caused by Chemotherapy with Cisplatin( double blind clinical trial)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221211056777N3

Enrollment

Registered

2023-08-18

Start date

2023-05-22

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer.

Interventions

Intervention 1: Intervention group: Cancer patients treated with cisplatin who will receive 80 mg curcumin capsules (Sina Curcumin Company) 2 times a day for 9 weeks. Intervention 2: Control group: Ca

Eligibility

Sex/Gender

All

Age

5 Years to No maximum

Inclusion criteria

Inclusion criteria: Cancer patients over 5 years of age who are being treated with cisplatin be the same in terms of medications and supplements taken Absence of kidney tumor No kidney failure

Exclusion criteria

Exclusion criteria: Diagnosing the presence of kidney stones in patients Patient non-cooperation

Design outcomes

Primary

Measure	Time frame
Serum levels of sodium. Timepoint: before the intervention and 8 weeks after the intervention. Method of measurement: Measurement of serum sodium level with a Flame Photometer.;Serum levels of potassium. Timepoint: before the intervention and 8 weeks after the intervention. Method of measurement: Measurement of serum potassium level with a Flame Photometer.;Serum levels of calcium. Timepoint: before the intervention and 8 weeks after the intervention. Method of measurement: Measurement of serum calcium level with a Flame Photometer.;Serum levels of magnesium. Timepoint: before the intervention and 8 weeks after the intervention. Method of measurement: Measurement of serum magnesium level with a Flame Photometer.;Serum levels of creatinine. Timepoint: before the intervention and 8 weeks after the intervention. Method of measurement: Measurement of serum creatinine level with a Flame Photometer creatinine.;Serum levels of blood urea nitrogen. Timepoint: before the intervention and 8 weeks after the intervention. Method of measurement: Measurement of serum blood urea nitrogen level with a Flame Photometer creatinine.;A quantitative measure of GFR. Timepoint: before the intervention and 8 weeks after the intervention. Method of measurement: Absolute measurement of glomerular filtration rate (GFR) according to creatinine clearance formula (GFR=Ucrv/Pcr1440).	—

Measure

Time frame

Serum levels of sodium. Timepoint: before the intervention and 8 weeks after the intervention. Method of measurement: Measurement of serum sodium level with a Flame Photometer.;Serum levels of potassium. Timepoint: before the intervention and 8 weeks after the intervention. Method of measurement: Measurement of serum potassium level with a Flame Photometer.;Serum levels of calcium. Timepoint: before the intervention and 8 weeks after the intervention. Method of measurement: Measurement of serum calcium level with a Flame Photometer.;Serum levels of magnesium. Timepoint: before the intervention and 8 weeks after the intervention. Method of measurement: Measurement of serum magnesium level with a Flame Photometer.;Serum levels of creatinine. Timepoint: before the intervention and 8 weeks after the intervention. Method of measurement: Measurement of serum creatinine level with a Flame Photometer creatinine.;Serum levels of blood urea nitrogen. Timepoint: before the intervention and 8 weeks after the intervention. Method of measurement: Measurement of serum blood urea nitrogen level with a Flame Photometer creatinine.;A quantitative measure of GFR. Timepoint: before the intervention and 8 weeks after the intervention. Method of measurement: Absolute measurement of glomerular filtration rate (GFR) according to creatinine clearance formula (GFR=Ucr*v/Pcr*1440).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShima Rahmati

Shahre-kord University of Medical Sciences

shimarahmati1987@gmail.com+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026